Brussels, Belgium (PRWEB UK) 19 September 2014
The partners of the ENTENTE-project together with the European Commission and EuropaBio (the European association for BioIndustries) are proud to announce the companies selected to present at the ENTENTE Life Sciences Investment Forum, taking place on October 9th at the Stanhope Hotel in Brussels, during the 2014 European Biotech Week.
The 28 European selected companies have been evaluated by the selection committee members among a pool of 100 innovative companies active in the Life Sciences sector and seeking investment opportunities and international exposure. The entrepreneurs will pitch their innovation, developments and needs in front of an international jury consisting of about 40 business angels, venture capitalists, corporate investors and other industry experts.
List of selected companies:
A2M Pharma GmbH [DE] - A2M Pharma is a neurology drug development spin-off from Schwarz Pharma.
BC Platforms [FI] - BC Platforms is a leading innovator in the rapidly growing genomic data management markets.
BCO Pharma Ltd. [IE] - The product is a combined drug and drug delivery device to treat otitis media.
BioTech Tools [BE] - BioTech Tools. is a clinical stage bio-pharmaceutical company committed to the development and commercialization of novel immunotherapy medicines for respiratory and food allergies based on the ASIT+ technology platform.
BIOXODES SA [BE] - Bioxodes is a start-up developing a natural product addressing blockbuster cardiovascular and potentially orphan markets.
CALCISCO AG [CH] - CALCISCO offers novel blood test for the assessment of calcification propensity and improved cardiovascular risk management.
CluePoints [BE] - CluePoints is a Central Statistical Monitoring solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.
Coimbra Genomics [PT] - Coimbra Genomics (CG) develops software tools for precision medicine.
CuraVac [BE] - CuraVac offers Therapeutic Vaccines for Autoimmune Diseases.
DBS System [CH] - DBS System is a blood collection revolution, enabling blood sampling anywhere, at any time and by anyone.
DermoSafe SA [CH] - DermoSafe SA provides a complete tele-medicine Solution & Services for melanoma early identification.
DualTPharma [NL] - DualTPharma develops highly-potent and proprietary pharmaceuticals for personalized cancer therapy.
ENTEROME [FR] - Enterome is pioneering the development of novel products to support personalized diagnostics & therapies and the clinical development of new drugs in microbiome-related diseases.
EyeTechCare [FR] - EyeTechCare's proprietary ultrasound technology offers non-invasive treatment of glaucoma.
Inflamalps SA [CH] - Inflamalps develops novel therapies for the treatment of autoimmune diseases of the eye.
LindaCare [BE] - LindaCare is a Remote Patient Telemonitoring Unified Dashboard & Productivity Tool.
Live Good [HR] - BodyRecog is an innovative ICT system for human body proportions recognition and analysis.
Magnomics [PT] - Magnomics offers an easy to use Point-of-Care in vitro diagnostic device for bacterial detection.
Nano Live [CH] - Nanolive has developed a disruptive proprietary technology, which allows for the very first time to explore a living cell in 3D without damaging it.
OMEICOS Therapeutics [DE] - Omeicos offers novel eicosanoid-like drugs for the treatment and prevention of atrial fibrillation.
OncoLab Diagnostics GmbH [AT] - OncoLab Diagnosticss focuses on production and commercialisation of proprietary innovative technologies to diagnose cancer earlier, and to detect and analyse traces of cancer in the patient's body.
PETsys Electronics - Medical PET Detectors, SA [PT] - Electronics and Detectors for PET scanners to early cancer's detection.
Plux [PT] - Plux creates compelling quantified self products for Physiotherapists and Researchers using an innovative biosignal monitoring platform.
Pragma Therapeutics [FR] - Pragma Therapeutics is a biopharmaceutical company in creation, developing innovative small molecules for the treatment of acute stress disorders.
Quanta Fluid Solutions [GB] - A pioneering UK-based medical devices company focusing on the development and commercialization of a novel cartridge-based haemodialysis system.
SamanTree Technologies [CH] - Digital microscopy company, with the vision to enable intra-operative point-of-care digital pathology for tumor surgery guidance.
TENSIVE [IT] - Tensive is an emerging biomedical startup that develops vascularizable biodegradable prostheses aiming to offer natural breast reconstruction/augmentation.
WISE s.r.l. [IT] - The new generation of leads for neuromodulation (NM) for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
The ENTENTE Life Sciences Investment Forum will be especially dedicated to strengthening the life sciences innovation potential in Europe through promoting and empowering innovative SMEs seeking financial facilitation and international exposure.
Throughout the day participants will have the opportunity to assist to inspiring panel discussions from key players of the industry and to innovative companies' presentations, and have plenty of networking opportunities including targeted one2one meetings.
The opening panel, moderated by Claus A. Andersson (Sunstone Capital) will focus on 'Key investment trends in biotech and medtech and see the contributions of Ruxandra Draghia-Akli (European Commission, Directorate Health Research) Mark Wilson (GlaxoSmithKline) Francesco De Rubertis (Index Ventures) Florent Gros (Novartis Venture Funds.
Find out more information here.
For further information on the ENTENTE Life Sciences Investment Forum please contact Annalisa Gardella from Europe Unlimited via mail at annalisa(at)e-unlimited(dot)com or via phone at +32 (0) 2 643 36 91.
ENTENTE (FP7 project) is the first European network to boost knowledge transfer activity in health research among academic and public organisations and industrial counterpart. The project promotes transnational collaboration among all stakeholders through networking activities, sharing experience and best practices and implementing an exchange programme for professionals of Technology Transfer in Health.
See more at: /entente-health.eu/
EuropaBio is the European Association for Bioindustries, bringing together bioscience companies from all fields of research and development, testing, manufacturing and distribution of biotechnology products. Its corporate, associate and national association members are involved in research, development, testing, manufacturing and commercialization of biotechnology products and processes, and have a wide range of activities: human and animal health care, diagnostics, bio-informatics, chemicals, crop protection, agriculture, food and environmental products and services. See more at: http://www.europabio.org
Read the full story at http://www.prweb.com/releases/2014/09/prweb12184185.htm
VIENNA, Sept. 19, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of positive interim clinical data for its lead candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in type 2 diabetes patients with high baseline HbA1c levels at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed markedly reduced levels of blood sugar in patients with poorly controlled type 2 diabetes. The results were presented by Dr. Robert R. Henry, Chief, VA Endocrinology & Metabolism and Professor of Medicine at UCSD. The overall results from the full 9-month HBL study and the FREEDOM-1 trial are expected to be announced in the fourth quarter of 2014.
In an oral presentation today, Dr. Henry reviewed the 6-month interim data from the FREEDOM-HBL trial, which enrolled T2D patients whose HbA1c levels exceeded the entrance criteria for the FREEDOM-1 phase 3 trial. The presentation, entitled "Efficacy and Tolerability of ITCA 650 (continuous subcutaneous exenatide) in Poorly Controlled Type 2 Diabetes with Baseline A1C >10%," included the following comments, results and conclusions:
- FREEDOM-1 is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of ITCA 650 in type 2 diabetes patients with an HbA1c between 7.5% and 10.0%.
- Patients who met all inclusion criteria for FREEDOM-1 but had HbA1c greater than or equal to 10% but less than or equal to 12% were enrolled in FREEDOM-HBL.
- On average, patients enrolled to FREEDOM-HBL had been diagnosed with T2D for 9 years and a majority was being treated with multiple background oral anti-diabetes therapies.
- Enrolling patients with high baseline HbA1c provides a robust opportunity to evaluate treatment response in a poorly controlled patient population.
- In this interim analysis, the addition of ITCA 650 resulted in mean HbA1c reductions greater than 3% in patients who reached 6 months of treatment.
- 30% of patients who reached 13 weeks of treatment (n=50) achieved the target HbA1c of less than 7%.
- ITCA 650 treatment was also accompanied by weight loss, which is not commonly observed in the treatment of patients with high baseline HbA1c.
- ITCA 650 has the potential to markedly improve glycemic control in patients with severe hyperglycemia and longstanding diabetes.
- ITCA 650 may offer potential benefits over existing oral and injectable therapies for type 2 diabetes via sustained glycemic control, favorable weight profile, improved tolerability, ensured adherence with once- or twice-yearly dosing, and no injections.
"More than 50% of people with type 2 diabetes remain inadequately controlled, often despite one or more treatments," said Dr. Henry. "These interim results may represent a very promising advance toward addressing that unmet need. There are a variety of reasons why there is this large segment of treatment-experienced type 2 diabetes patients who remain poorly controlled, including the progressive nature of the disease, poor adherence to therapy, and lack of aggressive treatment. These results appear to indicate that ITCA 650 can deliver potent effects both in terms of glycemic control and weight loss to a group of patients with very poorly controlled type 2 diabetes and for whom other therapies have failed. While ITCA 650 holds promise for the broad diabetes population, the unique delivery technology has the potential to address the contribution that sub-optimal efficacy and non-adherence play in poor glycemic control. With such promising interim results, I look forward with great anticipation to seeing the full data from the FREEDOM-HBL and FREEDOM-1 studies very soon."
About ITCA 650
ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is implanted sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time.
Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1C and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as a twice-daily and once weekly self-injection therapy for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM, and the first results from the FREEDOM-1 and FREEDOM-HBL (high baseline) phase 3 studies are expected to be reported in the fourth quarter of this year.
About Type 2 Diabetes
Type 2 diabetes is the most common form of diabetes and presents when the body either does not produce enough insulin or becomes resistant to insulin, resulting in high levels of blood sugar. According to a June 2011 Lancet publication by Danaei and colleagues, an estimated 347 million adults worldwide suffered from type 2 diabetes in 2008; that number is expected to rise to 472 million by 2030. It is estimated that pre-diabetes (impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG)) a condition that often leads to diabetes, affects a population roughly twice the size of the current diabetes population. The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded $400 billion in 2010. United Healthcare expects spending on diabetes and diabetes-related care to reach $500 billion by 2020 in the U.S. alone, and projects the cumulative cost of diabetes care will reach $3.4 trillion over the next decade.
About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, eliminating the need for life-long injections, ensuring compliance and persistency over time with up to once-yearly dosing, and by improving the tolerability of drug therapies. Delivering medicines just once or twice yearly virtually ensures patient compliance and persistency, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platforms. Intarcia is conducting a Phase 3-stage development program for type 2 diabetes and has additional early development programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.
Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.
SOURCE Intarcia Therapeutics, Inc.
FREMANTLE, Australia (PRWEB) September 19, 2014
Does one really possess the freedom of choice or is it another illusion to mask the inevitability of fate? Sometimes, the end is a gamble and one has to seek answers within the journey. In one epic tale of pure literary genius, author M.A. Hill evokes a poetic vision of the vast distances of the land and the dissolving polarities between the truth of reality and the mystery of illusion. "Trackless" (published by Xlibris AU) flexes the bounds of the imagination to reveal the intricacies of the fractured mind in a journey that follows no trails.
From the mansions of the wealthy and powerful, to beach shacks and remote desert camps, Aidan and Gwyneth struggle on a conquest of love, will and destiny. A successful architect, Aidan Randell throws away his career to gain freedom and follow his passion to be an artist. When he meets gifted musician Gwenyth Chamberlain, the ramparts of the safe world she has constructed shatter into chaos. Together, they embark on a journey both real and metaphorical in the undercurrent of destiny as mythic characters enmeshed in the Viking runestones -- he as Odin, a Norse god and she as Selene or Zelina the moon goddess. Magic and myth interweave to allow readers an inter-dimensional glimpse into the psyche of the victim and to illustrate the strength of the spirit to survive in unmapped landscapes of the desert and the mind.
Within its pages, the book teems with poetic language and the creative grace of original illustrations, showing the author's notable gift in the arts. "Trackless" is also Hill's creative uptake on the often hidden problem of child abuse in society and its effects on the adult survivors. "This story is a compassionate plea for understanding, tolerance and support for all the victims," Hill says. "I wanted to tell a story of survival that would reach not only fellow travelers who had experienced trauma but also those who share their lives."
Hill's masterful superimposition of antithetical themes displays an impressive contrast to sharpen the ultimate theme of survival – despite being lost, even with misadventures; hope carries one to a promising end. "Life is wonderful and the human spirit is invincible."
M.A. Hill is currently working on 'Windforce', the sequel to this first powerful novel.
By M.A. Hill
Hardcover | 6x9 in | 236 pages | ISBN 9781493135691
Softcover | 6x9 in | 236 pages | ISBN 9781493135684
E-Book | 236 pages | ISBN 9781493135677
Available at Amazon and Barnes & Noble
About the Author
M.A Hill was born in Tasmania and lives near Fremantle, Western Australia. She is an award winning playwright and poet. Her works embrace many dimensions of reality and fantasy. She strives for a better world and likes to travel by land, air and sea. As Annie Otness, she is an artist, working in paint, silk textiles and clay.
Xlibris Publishing Australia, an Author Solutions, LLC imprint, is a self-publishing services provider dedicated to serving Australian authors. By focusing on the needs of creative writers and artists and adopting the latest print-on-demand publishing technology and strategies, we provide expert publishing services with direct and personal access to quality publication in hardcover, trade paperback, custom leather-bound and full-color formats. To date, Xlibris has helped to publish more than 60,000 titles. For more information, visit xlibrispublishing.com.au or call 1800 455 039 to receive a free publishing guide. Follow us @XlibrisAus on Twitter for the latest news.
Read the full story at http://www.prweb.com/releases/2014/Trackless/prweb12184177.htm
Dallas, Texas (PRWEB) September 19, 2014
One of the major trends in the market is the unique properties of bioactive material, making it useful in different application sectors such as hard tissue repair, soft tissue repair, and tissue engineering.
Analysts forecast the Global Bioactive Material Market to grow at a CAGR of 13.30 percent over the period 2013-2018. According to the report, increase in aging population is one of the major drivers in the market. There will be an increased number of trauma, spinal and orthobiological surgeries because of the increased aging population, which will push the demand for bioactive materials.
Bioactive materials are part of the biomaterial family and are increasingly becoming popular due to their ability to react with body fluids and tissues without having a negative impact on the human health. They are extensively used as tissue replacement and tissue repair materials in surgical procedures. Bioactive materials are manufactured from materials such as ceramics, glass, glass-ceramics, and composites. The major end-users of bioactive materials are the Medical sector, followed by the Dentistry and Cosmetics sectors. Bioactive materials are commercially available in forms such as powders and nano-powders, granules, and injectable products and coatings.
Covered in this Report
The report covers the present scenario and the growth prospects of the Global Bioactive Material market for the period 2014-2018. The Global Bioactive Material market can be segmented into three: Bioactive Glass, Bioactive Ceramics, and Composites.
The Global Bioactive Material Market 2014-2018 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the APAC region, Europe, and North America; it also covers the Global Bioactive Material market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.sandlerresearch.org/purchase?rname=23278.
The report recognizes the following companies as the key players in the Global Bioactive Material Market: Biomet Inc., DePuy Synthes Inc., Medtronic Inc., Stryker Corp. and Zimmer Holdings Inc.
Other Prominent Vendors in the market are: 3Di, Aap Implantate, Arthrex, Baxter, Berkeley, Biomatlante, Curasan, Dentsply, Heraeus Kulzer, Integra Life Science, Kyocera, Novabone, Takiron and Wright Medical.
• Increased Aging Population
• For a full, detailed list, view our report Market Trend
• Increased use of Synthetic Material in Grafting
• For a full, detailed list, view our report Further, the report states that one of the main challenges that the market faces is the high cost of technology used to manufacture bioactive material. Bioactive material uses sol-gel technology for its preparation and uses in various biomedical applications, and the cost of this technology is very high. Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Bioactive Material Market Segmentation
Exhibit 3: Global Bioactive Material Market Segmentation by Product
Exhibit 4: Global Bioactive Material Market Segmentation by End-use
Exhibit 5: Global Bioactive Material Market Segmentation by Geography
Exhibit 6: Global Bioactive Material Market 2013-2018 (in US$ billion)
Exhibit 7: Global Bioactive Material Market Segmentation by End-users
Exhibit 8: Global Bioactive Material Market in Medical Sector 2013-2018(in US$ billion)
Exhibit 9: Global Bioactive Material Market in Dentistry Sector 2013-2018(in US$ billion)
Exhibit 10: Global Bioactive Material Market in Cosmetics Sector 2013-2018 (in US$ billion)
Exhibit 11: Global Bioactive Material Market Segmentation by Product
Exhibit 12: Global Bioactive Material Market Segmentation by Geography in 2013
Exhibit 13: Global Bioactive Material Market in North America 2013-2018 (in US$ billion)
Exhibit 14: Global Bioactive Material Market in Europe 2013-2018 (in US$ billion)
Exhibit 15: Global Bioactive Material Market in APAC 2013-2018 (in US$ billion)
Exhibit 16: Aging Population Growth 1995-2050(in millions)
Exhibit 17: DePuy Synthes: Business Units
Exhibit 18: Stryker: Business Segmentation by Revenue 2013
Exhibit 19: Stryker: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Stryker: Geographical Segmentation by Revenue 2013
Sandlerresearch.org (http://www.sandlerresearch.org/) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.
Indianapolis, Indiana (PRWEB) September 19, 2014
Indiana Fiber Network, LLC (IFN), the leading Indiana statewide Network Service Provider, announces the expansion of its Fiber Transport Services, adding Point of Presence (PoP) at 350 East Cermak in Chicago. By establishing a PoP at Cermak, IFN enables interconnect opportunities for Carriers, Service Providers, and Enterprise organizations looking for high bandwidth fiber transport service to US and Global Carriers.
According to IFN Vice President of Sales and Marketing August Zehner, establishing a PoP at Cermak in Chicago is a significant step in IFN's strategy to construct a regionally-diverse footprint to support the growing and evolving connectivity needs of organizations seeking redundancy for their head-end network access. "Cermak is at the heart of telecommunication access facilities for the Midwest, and a significant communications hub and distribution point for IP traffic. IFN's PoP at Cermak, leverages our state-of-the-art network and provides high bandwidth fiber transport options to Carrier and Enterprise customers alike," said Zehner.
Kelly Dyer, IFN President and CEO said: "IFN now has a PoP within one of the world's largest data center facilities, with access to more than 35 of the top domestic and international carriers. This enables IFN to be more responsive to customer's telecommunication needs, and to offer more competitive options to clients, not just in the U.S., but globally as well."
Indiana Fiber Network, LLC (IFN) was formed in March of 2002, whose ownership is comprised by 20 local exchange telephone companies throughout the state. They offer data center, Internet backbone, and data transport services over state-of-the-art Ethernet, CDWM, DWDM, and SONET fiber networks, with service in the State of Indiana and throughout the US, via a network of national carrier partners.
For More Information
For more information, please visit IFN's website at http://www.ifncom.net or call (317) 280-4636.
Read the full story at http://www.prweb.com/releases/2014/09/prweb12178194.htm
More Press ReleasesView Older Stories
Real Warriors Campaign Offers Resources and Support for Suicide Prevention Awareness Month
Beautiful Bridesmaid Dresses Designed And Created By AngelWeddingDress For The New Season
Aina Khan discusses unregistered Muslim marriages under English law on BBC Radio Gloucestershire
Karndean Designflooring transforms new look Good Housekeeping Institute
John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp's 80-City 2015 Concert Tour with Carlene Carter
Vault Solutions Named to Top Ten Companies to Watch List by Business NH Magazine
Huntsville Medical Doctor Announces First "Everyday Hero" Winner
Bridge School Benefit Concert Tickets: QueenBeeTickets.com Features 2014 28th Annual Benefit Concert Tickets for Shoreline Amphitheatre in Mountain View on October 25-26
2015 Ford F-250 Super Duty at Preston Ford in Maryland
Disabled Veterans National Foundation Commemorates POW/MIA Recognition Day
PCI Announces Acquisition of Biotec
TRU Community Care to Host Annual Signature Fundraiser as Speakeasy at New Marriott Hotel in Westminster, CO, on October 18, 2014
HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications
Hyatt Place Baltimore/Owings Mills Hotel Completes 1.5 Million Dollar Renovation
New at Summit Racing Equipment: Omix Ada, Teraflex, and RIPP Superchargers Parts and Accessories for Jeep
Pearls with Purpose Participates in "BRAlapalooza" to Raise Funds and Awareness for a Cause
PCI Announces Acquisition Of Biotec
Magna Announces Cooperation Regarding Regulatory Investigation
Jamorama.com – Guitar Lessons That Rock Review | Become a Real-Life Guitar Hero – Vinamy.com
BalaBit Announces the Availability of BalaBit's Shell Control Box 4 LTS
topseos-canada.com Announces Recommendations of 30 Top Search Marketing Companies in Canada for September 2014
Biotie: Selincro enters the market in France
Muscular Dystrophy Community, MDA Help MD-CARE Act Pass Senate, Bill Awaits President's Signature
Business & Life Strategist Doug Ottersberg to Speak Today at Investor Palooza
NYRIUS Introduces Songo® Bluetooth® Music Receiver for Streaming Laptops, Tablets, and Smartphones Wirelessly to Speaker Systems
SOMA Principal Michel Abboud Joins Developer Omniyat in Dubai To Present One at Palm Jumeirah
MagicQuinceaneraDress.com Has Added Some New Sweet 15 Quinceanera DressesTo Its Website Recently
Boy Catches Fire, Defies Death: 27 Years Later He Inspires Tampa Bay Burn Victim and Community How to Truly Live
VogueQueen.com's New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies
Ingrid Silvian Shares Her Childhood Experiences in WWII
Bloomberg LP becomes Official Supporter of the Natural Capital Declaration
Debt Consolidation USA Shares Common Tips When Getting An Auto Loan
Firmex Verified as HIPAA Compliant
Time to End Racism? Hollywood 27 Productions Launches "The Double Truth"
Analytics for Insurance Europe: 72% of insurers believe that Analytics is the biggest game-changer for their business in 2014-2015
China Film Group Purchases 200 Christie CP2220 DLP Digital Projectors to Expand Its Cinema Business
AliceBridal Launches its Wedding Dresses 2014 Promotion Today
MagicQuinceaneraDress.com Announces Its Magic Miss Quinceanera Dress Promotion for Autumn
With New Semester Under Way, LunaDress Unveils The Most Fashionable Prom Dresses
Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women
USA Welcomes Clients and Colleagues to Atlanta for ASIS 2014
NatureSweet Cherriots Wins 2014 Progressive Grocer Award
Shweiki Media Printing Company Announces Sponsorship of 2014 Texas Tribune FestIval
China Vanguard Attributable to Revenue Increase in Lottery Business & Property Development Business and Implement of Cost Control Initiatives
Norwegian LED Supplier Ladelys Announces the Launch of its New Website
LA Press Club's Entertainment Awards Changes Name to Include Arts Journalists, Extends Early Bird Deadline; Awards Gala to Honor Late Actor/Comedian Robin Williams
Excel Automation, a Service that Helps Save Time, is Now Available from Chicago Computer Classes
The Conference Board Leading Economic Index® (LEI) for Germany Declines
100 Top Professional Website Development Agencies Announced by bestwebdesignagencies.com for September 2014
New Findings of Independent Review of Alliance for Bangladesh Worker Safety Indicate Major Progress in Efforts to Improve Safety in Bangladesh Garment Factories